You are here

FDA Accepts Supplemental NDA For Intravenous Remodulin

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 31 /PRNewswire-FirstCall/ -- United Therapeutics Corporation announced today that its intravenous Remodulin supplemental New Drug Application (sNDA) has been accepted for review by the United States Food and Drug Administration (FDA). The sNDA was submitted on January 30, 2004 to add the intravenous route of delivery to the Remodulin label for the treatment of patients with pulmonary arterial hypertension. The FDA has until November 30, 2004 to issue an action letter for the sNDA.

"We are pleased to see that our accelerated efforts to bring broader treatment options to the pulmonary hypertension community have satisfied the threshold standards at the FDA," said Roger Jeffs, Ph.D., United Therapeutics' President and Chief Operating Officer.

Source: United Therapeutics Corporation

More Headlines

Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice
National Statistics Report Factors In Race, Ethnicity for the First Time
For Locally Advanced or Metastatic Triple-Negative Type Only